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Background: The presence of diabetes mellitus (DM) is associated with increased liver morbidity and mortality risk
in patients with chronic hepatitis B (CHB). Aim of this study was to identify factors associated with type 2 diabetes
mellitus (T2DM) in CHB patients.
Methods: A cross-sectional study with pair-matched controls was conducted in Nantong Third People’s Hospital,
Nantong University, China. From January 2008 to December 2012, a total of 1783 CHB patients were screened for
study subjects, among whom 207 patients with T2DM were enrolled as cases and 207 sex- and age-matched non-DM
patients as controls. Demographic, anthropometric, lifestyle, clinical, and laboratory data were obtained from each subject.
Results: In the univariate model, thirteen variables showed marked differences between the DM group and non-DM
group. Patients with longer duration of CHB (≥15 years) and alcoholic steatosis showed the highest likelihood of T2DM
(odds ratio = 5.39 and 4.95; 95% confidence intervals 2.76-10.53 and 1.65-14.91). In the multivariate adjusted analysis, three
CHB-related factors, namely high viral load, long duration of illness, and presence of cirrhosis, contributed to substantially
increase the likelihood of T2DM, in addition to the other five risk factors including family history of DM, low education
level, elevated triglycerides (TG), gamma-glutamyl transferase (GGT) levels, and presence of alcoholic steatosis.
Conclusions: Our findings suggest that high viral load, long duration of CHB, presence of cirrhosis, alcoholic steatosis and
several other factors may be potential risk factors for development of T2DM in CHB patients. It is of vital importance to
monitor glucose in high-risk CHB patients and aggressively intervene on modifiable risk factors.
Keywords: Chronic hepatitis B, Type 2 diabetes mellitus, Cross-sectional studyBackground
Hepatitis B virus (HBV) infection is a major global public
health issue with increasing complication and mortality
rates. As a highly endemic country, China bears an esti-
mated 93 million chronic HBV carriers and 30 million
chronic hepatitis B (CHB) patients [1]. Approximately
300,000 patients die from HBV-related liver diseases each
year in China [2]. Abnormalities in glucose metabolism
are common in patients with chronic liver diseases. The
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unless otherwise stated.control is associated with increased liver morbidity and
mortality risk in patients with HBV-cirrhosis [3]. Type 2
diabetes mellitus (T2DM) is independently associated with
the increased risk of hepatocellular carcinoma (HCC) in
CHB patients [4-6]. Although it is not clear whether HBV
infection has a relation with the development of diabetes
[7,8], identifying patients at high risk of diabetes and im-
proving diabetic control should be essential part of the
good care for the CHB patients.
While epidemiological studies have evaluated factors
associated with the presence of T2DM in general popu-
lation, the risk factors among CHB patients has not been
explored. The aim of this hospital-based cross-sectional
study was to identify risk factors associated with type 2
diabetes in patients with chronic hepatitis B.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
The CHB patients with T2DM (DM group) that formed
the basis of this study comprised all patients who fulfilled
the following criteria: (1) admitted to Nantong Third
People’s Hospital, Nantong University (Jiangsu Province,
China) between 1 January 2008 and 31 December 2012;
(2) diagnosed as chronic hepatitis B or hepatitis B cirrho-
sis, without evidence of viral hepatitis other than hepatitis
B; (3) complicated with newly diagnosed or previously
known T2DM; (4) duration of diabetes not longer than
that of hepatitis B surface antigen (HBsAg) positivity.
Non-DM controls were patients with CHB who had never
been diagnosed with diabetes, and they were matched for
sex and age with DM patients at a ratio of 1:1.
Chronic hepatitis B was diagnosed according to the
practice guideline of the American Association for the
Study of Liver Diseases [9]. All patients were known to
have positive hepatitis B surface antigen (HBsAg) for more
than six months. Diagnostic criteria for diabetes mellitus
include the following: symptoms of diabetes plus casual
plasma glucose concentration ≥ 11.1 mmol/L (200 mg/dL);
or fasting plasma glucose (FPG) levels ≥ 7.0 mmol/L
(126 mg/dL) on 2 separate occasions; or a 2-h postload
glucose ≥11.1 mmol/L during an oral glucose tolerance test
(OGTT) on 2 separate occasions [10,11]. The use of the
hemoglobin A1c (HbA1c) for the diagnosis of diabetes has
not been recommended in China [11]. Non-invasive
evaluation of fatty liver (steatosis) and cirrhosis was per-
formed with ultrasound, computed tomography scan or
transient elastography FibroTouch (Wuxi Hisky Medical
Technology, Beijing, China). The diagnosis of alcoholic
steatosis was made by documentation of alcohol excess
and evidence of fatty liver [12].
This study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki and was duly
approved by the ethics committee of Nantong Third
People’s Hospital, Nantong University. Written informed
consents for inclusion in the study were obtained from
all patients.
Data collection
The interview included questions related to the diagno-
sis and treatment of diabetes and hepatitis. A standard
questionnaire was administered by trained staff to obtain
the following information: age (year), sex, body mass
index (BMI; weight [kg]/height [m2]), systolic and dia-
stolic blood pressure (mmHg), marital status (yes/no),
educational level (primary/under, middle/high school,
college/above), history of CHB and T2DM (yes/no), date
of diagnosis of CHB and T2DM, family history of CHB
and T2DM (yes/no, first-degree relatives), alcohol con-
sumption (none; moderate, <30/20 g/d men/women; or
excessive, ≥ 30/20 g/d men/women) and smoking habit(none; moderate, < 10 cigarettes/d; or excessive, ≥ 10 ciga-
rettes/d).
Blood samples were collected from all subjects at time of
enrollment in study, after at least 8 h of fasting. FPG, HbA1c,
serum alanine aminotransferase (ALT), aspartate transamin-
ase (AST), bilirubin (TBIL), gamma-glutamyltransferase
(GGT), albumin (ALB), prothrombin time (PT), triglycerides
(TG), cholesterol (Chol), high density lipoprotein-cholesterol
(HDL), low density lipoprotein cholesterol (LDL) and cre-
atinine (CREA) were measured by biochemical tests using
an automatic biochemical analyzer (AU2700, Olympus,
Japan). Fasting plasma insulin (FPI) concentration was mea-
sured by two-site immunoenzymometric assay using Roche
Elecsys 2010 autoanalyzer (Roche Diagnostics, USA).
Serum alpha-fetoprotein (AFP) levels were measured by
an immunoluminometric assay on a random-access ana-
lyser (Architect i2000; Abbott Diagnostics, USA). Sero-
logical tests for HBsAg and HBeAg and the quantification
of HBV DNA load were determined as we described else-
where [13]. Serological tests for anti-HAV IgM, anti-HCV,
anti-HDV and anti-HEV were performed using enzyme
immunoassay methods.Statistical analysis
The continuous data were expressed as mean ± standard
deviation (SD) and categorical data as number or per-
cent. Comparison of continuous variables was done by
student t test. For categorical variables the chi-square or
Fisher’s exact test were used. In this analysis, T2DM was
taken as the dependent variable. Demographic, lifestyle,
medical history, clinical and laboratory factors were
taken as independent variables. Risk factors found sig-
nificant on univariate analysis were entered into multi-
variate logistic regression model. All statistical tests were
2-tailed, and a significance level (P) of 0.05 was used. The
statistical tests were performed using SPSS for Windows
version 20 (Chicago, IL).Results
During the study period, a total of 1,783 patients were
admitted to our hospital with the diagnosis of CHB.
After excluding patients who were co-infected with
other hepatitis viruses, 1732 patients were recruited for
the study. Their mean age was 45.8 ± 15.11 years, and
82.8% were men. There were 1343 CHB patients with no
evidence of cirrhosis, and 389 patients with hepatitis B
cirrhosis.
The diagnosis of diabetes mellitus was made for 219
CHB patients (49 newly diagnosed), among whom 207
patients met the inclusion criteria for the DM group. At
the index date, 207 non-DM controls were pair-matched
by sex and year of birth (Figure 1).
Figure 1 Flowchart of selection of study patients.
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As shown in Table 1, we observed a significant difference
of education level, history of smoking and alcohol drink-
ing, hypertension, duration of CHB, family history of CHB
and family history of DM between the DM and non-DM
groups (P < 0.05). Patients with T2DM had longer CHB
duration (9.26 ± 8.78 vs. 4.97 ± 6.22 years, P < 0.001). The
percentages of smoking or drinking history were signifi-
cantly higher among the diabetic patients when compared
to the non-diabetic patients. As expected, the diabetic pa-
tients also had more often a diagnosis of hypertension
(20.29% vs. 10.63%, P < 0.01). No significant difference
was found on BMI and marital status between the two
groups.
The proportion of patients with newly-diagnosed DM,
duration less than 2 years, 2 to 4.9 years, 5 to 9.9 years,
or more than 10 years, was 24%, 48%, 22%, 5% and 1%
respectively.
Clinical and laboratory features
The percentage of HBeAg-positive CHB patients was
significantly higher in the DM group than that in the
non-DM group (45.89% vs. 31.88%, P < 0.01). The mean
HBV DNA level was higher in the DM group, compared
with the non-DM group (5.34 ± 1.59 vs. 4.78 ± 1.96 lg
copies/mL, P < 0.01). Concerning the mean levels of
serum ALT, AST, TBIL, ALB, PT and AFP, there were no
significant differences found between the two groups.
However, for serum GGT and creatinine, the DM pa-
tients had higher levels than the non-DM controls. The
mean levels of plasma triglyceride, FPG, HbA1c andinsulin were significantly higher in the DM group than
in the non-DM group, whereas the HDL cholesterol
level was lower in the DM patients than in the non-DM
controls (Table 2).
The higher prevalence rates of steatosis and cirrhosis
were found in the DM group than the non-DM group
(13.53% vs. 4.83%, 24.64% vs. 16.43%, P < 0.05). The DM
group did not differ in the percentage of HCC from the
non-DM group (Table 2).
Antiviral therapy with nucleos(t)ide analogues (NAs)
was either initiated or continued in 38.16% (79/207) of
the DM patients and 35.27% (73/207) of the non-DM
patients (P = 0.55) at the time of enrollment. Entecavir
was the most common NA used at baseline diagnosis in
41 (19.81%) and 32 (15.46%), lamivudine in 24 (11.59%)
and 15 (7.25%), telbivudine in 3 (1.45%) and 10 (4.83%),
and lamivudine plus adefovir in 11 (5.31%) and 6
(2.90%) of DM and non-DM patients respectively. Of
the DM patients, 62 (29.95%) had diet-controlled DM,
72 (34.78%) were on insulin, 54 (26.09%) on metformin,
and 19 (9.18%) patients on sulphonylurea treatment.
Factors associated with T2DM in patients with CHB
A univariate logistic analysis was performed to quantify
the effect of potential risk factors on T2DM in CHB pa-
tients and generated the odds ratio (OR) and 95% confi-
dence interval (CI). Long duration of CHB (≥ 15 years)
and concomitant alcoholic steatosis were the two most
important and significant risk factors with OR (95% CI)
of 5.39 (2.76-10.53) and 4.95 (1.65-14.91) respectively.
The logistic regression analysis showed that high viral
load (HBV DNA ≥ 106copies/mL) significantly increased
the OR for developing type 2 diabetes (OR 2.84, 95% CI
1.73-4.66; P < 0.001), as did the presence of cirrhosis
(OR 1.66, 95% CI 1.02-2.70; P < 0.05), HBeAg positivity
(OR 1.81, 95% CI 1.21-2.70; P < 0.01), and family history
of CHB (OR 2.36, 95% CI 1.18-4.71; P < 0.05). Family
history of DM, low education level, smoking and alcohol
drinking habits, hypertension, high GGT and TG, and
were also associated with the increased risk of T2DM.
No significant effect of LDL level or presence of HCC
on the risk of diabetes was observed (Table 3).
In the multivariate adjusted model, T2DM remained
significantly associated with lower education level, family
history of DM, longer duration of CHB (≥ 15 years),
higher viral load (HBV DNA ≥ 106 copies/mL), presence
of cirrhosis, elevated GGT level (≥ 200 U/L, upper limit
of normal or ULN for 50 U/L), higher TG (≥ 1.7 mmol/
L), and alcoholic steatosis, as shown in Table 3.
Discussion
The liver plays an important role in the metabolism of
carbohydrates and is responsible for balance of blood
glucose [14]. In the presence of liver diseases, the
Table 1 Characteristics of demographic, lifestyle and
medical history
DM (n = 207) Non-DM (n = 207) P-value
Sex (Male/Female) 163/44 163/44 -
Age 51.34 ± 10.87 50.16 ± 10.49 0.262
< 40 34 33
40-59 118 124
≥ 60 55 43 0.469
BMI (kg/m2) 25.55 ± 4.30 24.86 ± 3.82 0.085
< 18.5 18 22
18.5-23.9 73 85
24-27.9 72 67
≥ 28 44 33 0.382
Education
Primary/under 106 73
Middle/High school 91 120
College/above 10 14 0.005
Marital status
Yes 189 196
Noa 18 11 0.178
History of smoking
No 132 171
Yes 75 36 < 0.001
History of alcohol drinking
No 138 174
Yes 69 33 < 0.001
Hypertension
No 165 185
Yes 42 22 0.007
Family history of CHB
No 175 192
Yes 32 15 0.008
Duration of CHB (year) 9.26 ± 8.78 4.97 ± 6.22 < 0.001
< 5 97 158
5-9.9 41 22
10-14.9 26 14
≥ 15 43 13 < 0.001
Family history of DM
No 187 199
Yes 20 8 0.019
Duration of DM (year)
0b 49 (23.67%)
0.1-1.9 99 (47.83%)




≥ 10 3 (1,45%)
aincluding divorced, widowed and unmarried.
bnewly-diagnosed.
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The alleged mechanisms consist of insulin resistance
(IR) in a hitherto unexplained way, direct pancreatic islet
β-cell damage, perhaps caused by an autoimmune
process via molecular mimicry or by dysregulation of
autoimmune functions [16]. Moreover, the etiology of
liver disease is important in the incidence of diabetes:
the non-alcoholic fatty liver disease (NAFLD), alcoholTable 2 Clinical and laboratory features
DM (n = 207) Non-DM (n = 207) P-value
ALT (U/L) 315.54 ± 435.76 245.23 ± 343.80 0.069
AST (U/L) 201.43 ± 272.55 172.34 ± 250.14 0.259
TBIL (μmol/L) 70.86 ± 83.05 57.34 ± 78.99 0.090
ALB (g/L) 34.21 ± 10.45 35.98 ± 9.57 0.073
PT (s) 16.51 ± 6.15 15.48 ± 5.94 0.083
GGT (U/L) 175.11 ± 162.11 121.12 ± 131.38 < 0.001
AFP (ng/mL) 64.96 ± 115.44 56.29 ± 118.27 0.451
HBeAg positivity 95 (45.89%) 66 (31.88%) 0.003
HBV DNA (lg copies/mL) 5.34 ± 1.59 4.78 ± 1.96 0.002
CREA (μmol/L) 82.32 ± 49.62 69.03 ± 38.21 0.002
TG (mmol/L) 1.84 ± 0.93 1.22 ± 0.62 < 0.001
Chol (mmol/L) 4.25 ± 3.06 3.84 ± 2.27 0.122
HDL (mmol/L) 1.08 ± 0.55 1.27 ± 0.69 0.002
LDL (mmol/L) 2.34 ± 1.31 2.10 ± 1.52 0.086
FPG (mmol/L) 8.67 ± 4.20 5.11 ± 1.28 < 0.001
HbA1c (%) 6.81 ± 2.07 6.12 ± 1.48 < 0.001
FPI (μU/mL) 9.42 ± 7.78 6.26 ± 3.33 < 0.001
Steatosis 28 (13.53%) 10 (4.83%) < 0.001
Cirrhosis 51 (24.64%) 34 (16.43%) 0.040
HCC (%) 12 (5.35%) 7 (3.21%) 0.240
NA treatmenta 79 (38.16%) 73 (35.27%) 0.541
DM treatment





Reference range of variables: ALT, 0-40 U/L; AST, 0-40 U/L; TBIL, 3.4-17.1 μmol/L;
ALB, 35-55 g/L; PT, 12.7-15.4 s; GGT, 0-50U/L; AFP, 0-13.4 ng/mL; HBV DNA, <3 lg
copies/mL); CREA, 44-115 μmol/L; TG, 0.48-1.88 mmol/L; Chol, 3.2-6.5 mmol/L; HDL,
0.83-1.96 mmol/L; LDL, 0-3.36 mmol/L; FPG, 3.9-5.6 mmol/L; HbA1c, 4.0-6.0%; FPI,
2-20 μU/mL.
Table 3 Univariate and multivariate-adjusted logistic analysis of risk factors of T2DM in CHB patients
Variable DM (n = 207) Non-DM (n = 207) Univariate Multivariate adjusted
OR (95% CI) P-value OR (95% CI) P-value
Education
Primary/under 106 73 1 1
Middle/High 91 120 0.52 (0.35-0.78) 0.002 0.60 (0.37-0.99) 0.046
College/above 10 14 0.49 (0.21-1.17) 0.108 0.54 (0.20-1.48) 0.231
Smoking
None 132 171 1 1
Moderate (< 10 cigarettes/d) 51 26 2.54 (1.50-4.29) < 0.001 1.60 (0.79-3.27) 0.195
Excessive (≥ 10 cigarettes/d) 24 10 3.11 (1.44-6.73) 0.004 2.22 (0.91-5.34) 0.080
Alcohol Consumption
None 138 174 1 1
Moderate (< 30/20 g/d men/women) 29 19 1.92 (1.04-3.58) 0.039 1.64 (0.74-3.60) 0.222
Excessive (≥ 30/20 g/d men/women) 40 14 3.60 (1.88-6.89) < 0.001 2.09 (0.90-4.83) 0.086
Hypertension
No 165 185 1 1
Yes 42 22 2.14 (1.23-3.74) 0.007 1.46 (0.74-2.88) 0.281
Family history of DM
No 187 199 1 1
Yes 20 8 2.66 (1.14-6.19) 0.023 3.85 (1.43-10.39) 0.008
Family history of CHB
No 175 192 1 1
Yes 32 15 2.34 (1.23-4.47) 0.010 1.45 (0.70-2.98) 0.314
Duration of CHB (year)
<5 97 158 1 1
5-9.9 41 22 3.04 (1.71-5.40) < 0.001 4.32 (2.21-8.44) < 0.001
10-14.9 26 14 3.03 (1.51-6.07) 0.002 2.13 (0.97-4.69) 0.061
≥15 43 13 5.39 (2.76-10.53) < 0.001 5.80 (2.72-12.37) < 0.001
GGT (U/L)
<50 31 58 1 1
50-199 96 106 1.69 (1.01-2.84) 0.045 1.54 (0.83-2.87) 0.174
≥200 80 43 3.48 (1.96-6.17) < 0.001 3.79 (1.89-7.59) < 0.001
HBeAg positive
No 112 141 1 1
Yes 95 66 1.81 (1.21-2.70) 0.004 1.33 (0.80-2.22) 0.275
HBV DNA (copies/mL)
< 103 38 68 1 1
103-9.9*105 58 62 1.50 (0.89-2.55) 0.130 1.27 (0.66-2.43) 0.468
≥ 106 111 77 2.84 (1.73-4.66) < 0.001 1.94 (1.05-3.58) 0.033
High TG (≥ 1.7 mmol/L)
No 144 181 1 1
Yes 63 26 3.05 (1.84-5.05) < 0.001 2.12 (1.15-3.90) 0.016
Low HDL (< 1.0 mmol/L)
No 138 153 1
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Table 3 Univariate and multivariate-adjusted logistic analysis of risk factors of T2DM in CHB patients (Continued)
Yes 69 54 1.42 (0.93-2.16) 0.107
Steatosis
No 179 197 1
Non-alcoholic 10 6 1.83 (0.65-5.15) 0.249 1.28 (0.35-4.78) 0.708
Alcoholic 18 4 4.95 (1.65-14.91) 0.004 5.24 (1.50-18,29) 0.009
Cirrhosis
No 156 173 1 1
Yes 51 34 1.66 (1.02-2.70) 0.040 2.00 (1.11-3.61) 0.020
HCC
No 195 200 1
Yes 12 7 1.76 (0.68-4.56) 0.246
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ated with diabetes [17-19].
Among the few previous studies about the relationship
of HBV infection and diabetes, findings were controver-
sial [7,8]. A positive association was found in a cohort
study in which HBsAg-positive Asian American subjects
had a higher risk of incident diabetes (OR 9.73; 95% CI,
3.30-28.69), compared with non-infected controls [7]. In
contrast, in a 10-year Taiwanese community-based co-
hort study, persons with asymptomatic chronic HBV in-
fection did not have an increased risk of diabetes, in
comparison with non-HBV controls [8]. In this hospital-
based cross-sectional study with pair-matched controls,
CHB-related variables, namely duration of CHB, HBV
viral load and cirrhosis were associated with patients
with type 2 diabetes mellitus compared to those without.
IR, associated with impaired cellular response of the
insulin signaling pathway, is a risk factor for T2DM. The
association between CHB and IR also remains unclear
[20-22]. In this study, we observed the hyperinsulinemia
in diabetic CHB patients, suggesting the body responded
by increasing serum insulin concentrations to compensate
IR. BMI is supposed to be an important potential inter-
mediary or confounder for diabetes risk association. But
we observed no difference of the mean BMI between the
DM group and non-DM group. It might be explained in
part by the fact that Chinese develop DM at a notably
lower BMI [23] and by the low rate of newly diagnosed
DM in this study.
HBV infection status in these CHB patients was classi-
fied by HBeAg status and HBV DNA level in our study.
Univariate analysis showed that the percentage of patients
with positive HBeAg or high HBV DNA in the case group
was significantly higher than that of control group.
Multivariate-adjusted Logistic analysis further confirmed
that high viral load (HBV DNA ≥ 106copies/mL) was inde-
pendently associated with T2DM in patients with CHB.
We noted a significant association between CHB duration
and T2DM risk in our study population, a four-fold higherdiabetes risk for subjects with CHB duration ≥ 5 years than
for those with a shorter duration (< 5 years). A positive as-
sociation between cirrhosis and diabetes risk was also ob-
served. These results suggest that the association between
CHB and diabetes risk may be a time- and severity-
dependent relationship.
It is hard to accurately determine the severity of
chronic hepatitis on the basis of physical examination
and liver biochemistry. Liver enzymes ALT and GGT
elevation have been reported to be independent predic-
tors for diabetes in the general population [24]. In our
stratified analysis, we found that the elevation of GGT
(≥ 4 ULN), but not ALT, was an independent risk factor
of diabetes after adjustment for other variables.
Fatty liver in HBV-infected patients seems to be as fre-
quent as in the general population [20,25]. Glucose, the
key component of diabetes, is overproduced by the fatty
liver. In a previous nine-year study, the fatty liver index
(FLI) for evaluating the extent of liver fat has been found
predictive of incident diabetes [26]. In this study, alcoholic
steatosis is seen more commonly in the DM patients. Both
alcohol consumption and alcoholic steatosis increased the
risk of diabetes in the univariate analysis. After multivari-
ate adjustment, alcoholic steatosis remained to be an inde-
pendent risk factor. This finding suggests that alcoholic
liver disease plays an important role in the development
of diabetes in relatively lean Chinese population.
When the family history of DM, a well-known risk factor
for DM, was entered through logistic model, the correl-
ation between CHB-related factors and DM remained sig-
nificant. This finding, in consistence with previous studies
[15], indicates that liver injury per se is associated with
DM, while the family history of DM is only an adjunctive
factor. As similar observations from general population
[23], elevated serum triglyceride level and lower educa-
tional level were also significantly associated with an in-
creased risk of diabetes among these CHB patients.
Although we were able to demonstrate a potential
positive association with T2DM and three CHB-related
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proving a firm cause-effect relationship due to several
limitations. It is apparent that such a cross-sectional
study with pair-matched controls generally do not allow
interpretation with respect to an etiological or causal rela-
tion. In an attempt to establish a temporal relationship,
we aimed to assess exposure to CHB prior to onset of
DM, implicating that this exposure might trigger some
metabolic pathways for DM. Cirrhosis was identified as an
independent risk factor for DM, we were only able to sug-
gest a potential relationship between the severity of CHB
and the incidence of DM. Besides, our patient population
is a selected hospital-based population, which may not
represent the CHB population as a whole. These problems
could be addressed in a population-based cohort study
which follow patients with HBV from time of infection for
a long enough time to the incidence of diabetes.
Conclusions
The findings of our study indicate that the risk of T2DM
in CHB patients is not homogeneous and varied sub-
stantially due to the presence of quite a few potential
diabetic risk factors. In addition to other risk factors,
such as family history of diabetes, low education level,
elevated serum GGT and TG level, presence of alcoholic
steatosis, three CHB-related features, i.e. long duration
of CHB, high HBV load and presence of cirrhosis, contrib-
ute to substantially increase the likelihood of T2DM. Des-
pite its role as an independent predictor of cardiovascular,
renal and hepatic outcomes, the importance of monitoring
diabetes and acting on modifiable risk factors among CHB
patients is still underestimated. Physicians should screen
for diabetes in patients at a greater risk, in order to im-
prove care, target lifestyle and medical interventions, and
reduce the clinical and economic burden of both hepatic
and diabetic complications.
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